Patents by Inventor Hodjattallah Rabbani

Hodjattallah Rabbani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAGNOSTIC AND THERAPEUTIC TARGET
    Publication number: 20140161809
    Abstract: An in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates an increased probability of said subject suffering from cancer. The disclosure further relates to antibodies specific for PRELP and their use in diagnosis and therapy as well as a method for indicating a cell as a cancer cell.
    Type: Application
    Filed: January 30, 2014
    Publication date: June 12, 2014
    Applicant: Avicenna Research Institute
    Inventor: Hodjattallah Rabbani
  • Diagnostic and therapeutic target
    Patent number: 8658380
    Abstract: The present invention relates to an in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates an increased probability of said subject suffering from cancer. It further relates to antibodies specific for PRELP and their use in diagnosis and therapy as well as a method for indicating a cell as a cancer cell.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: February 25, 2014
    Assignee: Avicenna Research Institute
    Inventor: Hodjattallah Rabbani
  • BIOLOGICAL INHIBITORS OF ROR1 CAPABLE OF INDUCING CELL DEATH
    Publication number: 20140004156
    Abstract: The invention relates to antibodies and siRNA molecules for inducing cell death by the specific binding of ROR1, domains thereof of nucleotide molecules encoding ROR1. There are also provided methods involving and uses of the antibodies and siRNA molecules of the invention.
    Type: Application
    Filed: December 10, 2010
    Publication date: January 2, 2014
    Inventors: Hakan Mellstedt, Hodjattallah Rabbani, Ingrid Teige
  • DIAGNOSTIC AND THERAPEUTIC TARGET
    Publication number: 20130039917
    Abstract: The present invention relates to an in vitro method for assessing the risk that a subject suffers from a cancer, comprising measuring the expression level of Proline/arginine-rich end leucine repeat protein (PRELP) in cells from said subject, wherein an increased expression level of PRELP, as compared to healthy donors, indicates an increased probability of said subject suffering from cancer. It further relates to antibodies specific for PRELP and their use in diagnosis and therapy as well as a method for indicating a cell as a cancer cell.
    Type: Application
    Filed: October 28, 2011
    Publication date: February 14, 2013
    Inventor: Hodjattallah Rabbani